Marksans Pharma Toekomstige groei
Future criteriumcontroles 3/6
Marksans Pharma zal naar verwachting groeien in winst en omzet met respectievelijk 18.3% en 13.8% per jaar. De winst per aandeel zal naar verwachting groeien met 18.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 15.8% zijn.
Belangrijke informatie
18.3%
Groei van de winst
18.37%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 16.1% |
| Inkomstengroei | 13.8% |
| Toekomstig rendement op eigen vermogen | 15.80% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 28 May 2026 |
Recente toekomstige groei-updates
Analyseartikel • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Analyseartikel • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Analyseartikel • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Analyseartikel • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Recent updates
Narratiefupdate • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Nieuw narratief • Jun 01
Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?Analyseartikel • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Analyseartikel • May 28
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Analyseartikel • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Analyseartikel • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Narratiefupdate • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Analyseartikel • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narratiefupdate • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Analyseartikel • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Analyseartikel • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Analyseartikel • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...Analyseartikel • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...Analyseartikel • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Analyseartikel • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Analyseartikel • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Analyseartikel • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
Nieuw narratief • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Analyseartikel • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Analyseartikel • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Analyseartikel • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Analyseartikel • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Analyseartikel • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Analyseartikel • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2029 | 45,800 | 7,689 | N/A | 6,595 | 1 |
| 3/31/2028 | 39,311 | 6,113 | 4,228 | 5,403 | 3 |
| 3/31/2027 | 34,903 | 5,377 | 2,888 | 4,790 | 2 |
| 3/31/2026 | 29,509 | 4,179 | 3,276 | 4,581 | N/A |
| 12/31/2025 | 28,033 | 3,603 | N/A | N/A | N/A |
| 9/30/2025 | 27,307 | 3,517 | 346 | 2,047 | N/A |
| 6/30/2025 | 26,522 | 3,501 | N/A | N/A | N/A |
| 3/31/2025 | 26,228 | 3,806 | 337 | 2,067 | N/A |
| 12/31/2024 | 24,744 | 3,683 | N/A | N/A | N/A |
| 9/30/2024 | 23,787 | 3,470 | 520 | 2,169 | N/A |
| 6/30/2024 | 22,680 | 3,338 | N/A | N/A | N/A |
| 3/31/2024 | 21,774 | 3,137 | 216 | 2,304 | N/A |
| 12/31/2023 | 21,034 | 3,164 | N/A | N/A | N/A |
| 9/30/2023 | 19,971 | 2,965 | 894 | 2,528 | N/A |
| 6/30/2023 | 19,184 | 2,743 | N/A | N/A | N/A |
| 3/31/2023 | 18,521 | 2,663 | 1,838 | 2,374 | N/A |
| 12/31/2022 | 17,842 | 2,123 | N/A | N/A | N/A |
| 9/30/2022 | 16,670 | 2,004 | 972 | 1,286 | N/A |
| 6/30/2022 | 15,756 | 1,847 | N/A | N/A | N/A |
| 3/31/2022 | 14,908 | 1,868 | 529 | 993 | N/A |
| 12/31/2021 | 14,069 | 2,367 | N/A | N/A | N/A |
| 9/30/2021 | 14,026 | 2,473 | 883 | 1,336 | N/A |
| 6/30/2021 | 14,064 | 2,518 | N/A | N/A | N/A |
| 3/31/2021 | 13,762 | 2,385 | 1,322 | 1,786 | N/A |
| 12/31/2020 | 13,817 | 2,018 | N/A | N/A | N/A |
| 9/30/2020 | 13,142 | 1,724 | 1,839 | 2,478 | N/A |
| 6/30/2020 | 12,203 | 1,476 | N/A | N/A | N/A |
| 3/31/2020 | 11,344 | 1,208 | 1,734 | 2,333 | N/A |
| 12/31/2019 | 10,463 | 879 | N/A | N/A | N/A |
| 9/30/2019 | 9,972 | 834 | N/A | 416 | N/A |
| 6/30/2019 | 10,099 | 780 | N/A | N/A | N/A |
| 3/31/2019 | 10,001 | 804 | N/A | 274 | N/A |
| 12/31/2018 | 9,523 | 666 | N/A | N/A | N/A |
| 9/30/2018 | 9,223 | 582 | N/A | N/A | N/A |
| 6/30/2018 | 9,272 | 463 | N/A | N/A | N/A |
| 3/31/2018 | 9,127 | 358 | N/A | 501 | N/A |
| 12/31/2017 | 8,918 | 343 | N/A | N/A | N/A |
| 9/30/2017 | 8,949 | 275 | N/A | N/A | N/A |
| 6/30/2017 | 8,015 | 187 | N/A | N/A | N/A |
| 3/31/2017 | 7,672 | 113 | N/A | 141 | N/A |
| 12/31/2016 | 7,926 | 70 | N/A | N/A | N/A |
| 9/30/2016 | 7,948 | 136 | N/A | N/A | N/A |
| 6/30/2016 | 8,699 | 481 | N/A | N/A | N/A |
| 3/31/2016 | 8,933 | 785 | N/A | 308 | N/A |
| 12/31/2015 | 8,536 | 1,093 | N/A | N/A | N/A |
| 9/30/2015 | 8,495 | 1,191 | N/A | N/A | N/A |
| 6/30/2015 | 8,045 | 1,154 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei MARKSANS ( 18.3% per jaar) ligt boven de spaarquote ( 6.9% ).
Winst versus markt: De winst van MARKSANS ( 18.3% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 16.2% per jaar).
Hoge groeiwinsten: De winst van MARKSANS zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van MARKSANS ( 13.8% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.8% per jaar).
Hoge groei-inkomsten: De omzet van MARKSANS ( 13.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen MARKSANS zal naar verwachting over 3 jaar laag zijn ( 15.8 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/08 10:31 |
| Aandelenkoers aan het einde van de dag | 2026/06/05 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Marksans Pharma Limited wordt gevolgd door 4 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |